Gene expression in eukaryotes requires distinct co-factor complexes that assemble on the RNA polymerase II (pol II) core enzyme and help it to carry out the sequential steps of the transcription cycle, including initiation, elongation, termination, and RNA 3′-end processing (
Cho, 2007;
Pandit et al., 2008). The timing of co-factor assembly is regulated, in part, by reversible covalent and non-covalent modification of the carboxy terminal domain (CTD) of Rpb1, the largest subunit of pol II (
Egloff and Murphy, 2008;
Hirose and Ohkuma, 2007;
Phatnani and Greenleaf, 2006).
Covalent modification of the CTD involves phosphorylation and dephosphorylation of Ser2 and Ser5 (
Chapman et al., 2007;
Palancade and Bensaude, 2003;
Patturajan et al., 1998;
Phatnani and Greenleaf, 2006), and Ser7 (
Chapman et al., 2007;
Egloff et al., 2007;
Keogh et al., 2003) within the CTD heptad repeat (Tyr
1-Ser
2-Pro
3-Thr
4-Ser
5-Pro
6-Ser
7). Phosphorylation of Ser5 is enhanced at the 5′ ends of genes and is associated with initiation complex formation, 5′-capping, and the transition to elongation, while phosphorylation of Ser2 increases toward the 3′ end of genes and is associated with elongation and termination (
Bird et al., 2004;
Kobor and Greenblatt, 2002;
Licatalosi et al., 2002;
McCracken et al., 1997;
Schroeder et al., 2000). The role of Ser7 phosphorylation in yeast is unknown. A number of conserved Ser2- and Ser5- specific CTD kinases and phosphatases have been identified, and many co-factor proteins required for transcription and chromatin modification specifically associate with either Ser2- or Ser5- phosphorylated forms of the CTD (reviewed in
Egloff and Murphy, 2008).
Much less is known about non-covalent changes to the CTD such as prolyl isomerization. The CTD repeat contains two Ser-Pro peptide bonds that are targets of enzymes known as peptidyl prolyl
cis/
trans isomerases (Schiene and Fischer, 2000). Isomerization is predicted to cause dramatic conformational changes in the CTD that likely affect co-factor binding (
Cramer, 2006;
Meinhart et al., 2005). The CTD isomerase Ess1 was identified in
Saccharomyces cerevisiae (
Hanes et al., 1989;
Hani et al., 1995), and has a human ortholog, Pin1 (
Lu et al., 1996;
Lu and Zhou, 2007). Ess1 deletion is lethal in yeast and mutants undergo mitotic arrest (
Hanes et al., 1989;
Wu et al., 2000). Pin1 knockdowns and knockouts also show cell cycle defects (
Fujimori et al., 1999;
Liou et al., 2002;
Lu et al., 1996), and Pin1 misregulation has been associated with cancer and neurological disorders (
Lu and Zhou, 2007;
Yeh and Means, 2007). Pin1 has been shown to interact with a wide variety of target proteins (
Joseph et al., 2003).
Both Ess1 and Pin1 bind Ser2- and Ser5- phosphorylated forms of the CTD but they do not bind unphosphorylated CTD (
Morris et al., 1999;
Verdecia et al., 2000;
Yaffe et al., 1997;
Zhang et al., 2002). Ess1 binds and isomerizes phospho-Ser5-Pro6 (P-Ser5-Pro6) ~5-fold better than phospho-Ser2-Pro3 (P-Ser2-Pro3) within the CTD (
Gemmill et al., 2005), consistent with genetic experiments identifying P-Ser5-Pro6 as a major functional target (
Wilcox et al., 2004). Genetic experiments also indicate that
ESS1 plays important roles in initiation, elongation, and termination of pol II transcription (
Wilcox et al., 2004;
Wu et al., 2001;
Wu et al., 2003;
Wu et al., 2000;
Krishnamurthy et al., 2009). Indeed,
ESS1 (
PTF1) was recovered in a screen for mutations that impair transcription termination in a readthrough reporter assay (
Hani et al., 1995).
In yeast, two distinct pathways for transcription termination have been described (
Kim et al., 2004;
Kim et al., 2006;
Lykke-Andersen and Jensen, 2007;
Rondon et al., 2008;
Steinmetz and Brow, 1996;
Steinmetz et al., 2001). The major pathway is the canonical mRNA termination pathway that results in 3′ cleavage and polyadenylation of transcripts derived from protein coding genes. This pathway requires members of the CFI complex including Hrp1, Pcf11, Rna14, and Rna15, and the CPF complex including Cft2, Pap1, Pta1, Pti1, Ref2, Rat1, Ssu72 and Swd2 (
Aranda and Proudfoot, 2001;
Birse et al., 1998;
Buratowski, 2005;
Nedea et al., 2003). The products of this pathway are relatively stable mRNAs that carry long (~70 nt) poly(A) tails and are exported to the cytoplasm for translation (
Barabino and Keller, 1999). In contrast, other pol II transcripts that are typically small, nonpolyadenylated, and largely restricted to the nucleus, are terminated by an alternative pathway that is dependent upon Nrd1 (
Steinmetz et al., 2001). The Nrd-1 pathway is used to terminate most small nucleolar RNAs (snoRNAs), small nuclear RNAs (snRNAs), cryptic unstable transcripts (CUTs), and some short mRNAs (
Arigo et al., 2006;
Kim et al., 2006;
Steinmetz et al., 2001;
Thiebaut et al., 2006). This pathway utilizes a distinct, but partially overlapping set of proteins that includes Glc7, Nrd1, Nab3, Paf1, Pcf11, Rna14, Rna15, Sen1, Ssu72, Swd2 and Trf4 (
Lykke-Andersen and Jensen, 2007). It is not yet established which pathway is used for a newly described set of small transcripts called SUTs (stable unannotated transcripts;
Xu et al., 2009).
Here we sought to identify Ess1 target genes and study the role of Ess1 in their expression. Using genome-wide approaches, we found that about 10% of the genome is mis-regulated in ess1 mutants, and that the most prominent defect is a failure to correctly terminate snoRNA gene transcription. Readthrough of snoRNAs in ess1 mutants is similar to that observed in nrd1, nab3, pcf11 and paf1-complex mutants, and indeed genetic interactions and chromatin immunoprecipitation (ChIP) data indicate that Ess1 is linked to the Nrd1 pathway. As expected if Ess1 functions in the Nrd1 pathway, ess1 mutants show a failure to process CUTs and upstream regulatory RNAs (uRNAs), whose misregulation leads to constitutive expression (or repression) of downstream ORFs. We also show that Ess1 controls the phosphorylation state of the CTD and present a model for how Ess1-directed isomerization of the CTD plays a critical role in Nrd1-dependent transcription termination.